Radiolabeled 89Zr-DFO-girentuximab PET/CT can accurately and noninvasively identify clear cell renal carcinoma, with minimal toxicity, say researchers reporting results from the phase 3 ZIRCON trial.
SAN FRANCISCO — A novel, noninvasive method was able to accurately and noninvasively identify clear cell renal carcinoma , and shows promise for differentiating indeterminant renal masses, say researchers reporting the phase 3 ZIRCON study with radiolabeledDetection of renal masses can present a considerable patient management challenge.
"Clear cell RCC accounts for 75% of RCC and causes about 90% of deaths," he said."Renal mass biopsy is invasive and anatomic imaging cannot reliably distinguish between benign/malignant renal masses." The sensitivity and specificity for the key secondary endpoints was 85% and 90%. For all evaluable patients, positive and negative predictive values were ≥ 91.7% and ≥ 73.7%.
The REDECT trial was a smaller study with 195 patients, that Fox Chase helped lead, he explained. That study showed superior sensitivity and specificity for iodine-124 girentuximab PET/CT in the detection of ccRCC when compared with contrast enhance CT .
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Seven Knights 2 Releases New Update Featuring New Legendary HeroNetmarble has a new update available right now for SevenKnights2 as you get several upgrades and a new Legendary Hero.
続きを読む »
Tiger cub rescued in New Mexico finds new home in ColoradoA Bengal tiger cub found by Albuquerque police in a dog crate last month now has a new home in Colorado.
続きを読む »
Meta launches subscription plans for Facebook, InstagramMeta is testing a new verification service called Meta Verified in New Zealand and Australia.
続きを読む »
Report: Russell Westbrook plans to sign with Clippers after contract buyout from Jazz, per agentRussell Westbrook, a nine-time All-Star and two-time NBA scoring champion who began the season with the Los Angeles Lakers, is expected to clear waivers and return to LA with a different team. Story:
続きを読む »